The minimal important changes of percentage and absolute improvement of EASI and SCORAD scores in adults and children with AD was determined.
FB-401 is a topically applied live biotherapeutic that consists of 3 therapeutic strains of commensal Roseomonas mucosa.
The regulatory application is supported by data from 3 randomized, double-blind, placebo-controlled phase 3 studies.
The goal of this study was to determine whether adding topical antibiotics to topical corticosteroids led to additional clinical improvement in infants with moderate to severe atopic dermatitis during a short-term follow-up period.
Patients with scalp involvement and their patch testing outcomes were characterized in this study analyzing allergic contact dermatitis.
Investigators sought to assess the overall keratinocyte carcinoma risk and by subtype in adults with atopic dermatitis exposed to topical calcineurin inhibitors.
A study sought to characterize adults with atopic dermatitis who initiated dupilumab and evaluate persistence on therapy.
Drug survival of dupilumab compared with cyclosporin, the reasons for drug discontinuation, and the predictive parameters of drug survival were analyzed.
The efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate to severe atopic dermatitis is assessed.
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that blocks the activation of the JAK-STAT pathway.